Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
暂无分享，去创建一个
G. Follows | A. Howes | A. Kater | L. Ysebaert | T. Robak | M. Šimkovič | A. Osterborg | C. Niemann | M. Levin | C. Owen | T. Munir | A. Janssens | K. Qi | Qianya Qi | D. Stevens | O. Benjamini | M. Yağcı | S. Voloshin | D. B. Caces | C. Moreno | V. Vorobyev | K. Baeten | N. Schuier | Srimathi Srinivasan | Lori Parisi